cMpl Inhibitors
2 drugsAbout cMpl
cMpl, or thrombopoietin receptor, is essential for platelet production and blood clotting. It regulates megakaryocyte development, proliferation, and differentiation. cMpl signaling pathways are crucial for maintaining adequate platelet levels.
cMpl is a therapeutic target for modulating platelet production. Currently, there is no genetic evidence directly linking cMpl to specific diseases, but its role in hematopoiesis makes it relevant to certain conditions.
Two FDA-approved small molecule drugs target cMpl: ELTROMBOPAG OLAMINE (Revolade) and Alvaiz. These drugs, developed by Zydus Pharms and Teva, respectively, are used in infectious disease.
Top cMpl Drugs
ZYDUS PHARMS and Teva are the only two companies with approved cMpl-targeting drugs.
The limited number of players suggests a concentrated market, but also an opportunity for new entrants.
cMpl Drug Modality Landscape
Modalities
Routes of Administration
cMpl is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
cMpl Clinical Trials 97 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on cMpl. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 14 | 6 | 2 | 70% |
| Phase 2 | 53 | 36 | 7 | 10 | 84% |
| Phase 3 | 13 | 8 | 3 | 2 | 73% |
| Phase 4 | 9 | 5 | 1 | 3 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
cMpl Drug Approval Timeline (2023 - 2024)
The first cMpl-targeting drug was approved in 2023, with the most recent in 2024.
Recent approvals indicate continued interest in cMpl, but further market analysis is needed to assess saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 49 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on cMpl. A trial counts if an approved drug acting on cMpl is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.